GlobeNewswire by notified

Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine

Share

WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. These funds advance development of a vaccine against Marburg virus disease, a virus that is related to Ebola Zaire which killed 2200 people during the last major outbreak that ended in 2020.

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial. Marburg is among the world’s deadliest viruses, resulting in the death of approximately half the people the virus infects. Currently, there are no approved vaccines or treatments for the disease. As recently as July this year, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for medical therapies.

The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies. The Phase 2 clinical trial in the U.S. will begin after Sabin has initiated a same-stage trial in Africa, currently scheduled for 2023. Sabin will also undertake a non-clinical study on the vaccine candidate during this phase.

“Beginning Phase 2 clinical trials for the Marburg vaccine is a pivotal milestone for us and we appreciate BARDA’s continued confidence in our work and support for this critical next step,” says Sabin Chief Executive Officer Amy Finan. “Vaccines remain our best bet against death and disability from deadly viruses. I am hopeful that in the years ahead, we can offer this life-saving vaccine to every person who needs it.”

In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan. With BARDA now exercising the latest option of that contract, Sabin’s Ebola and Marburg Research & Development program, to date, has been awarded $98.6 million.

BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C000555.

Learn more about Sabin’s Marburg and Ebola Sudan Program.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of the hemorrhagic fevers caused by filoviruses has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

Media contact:

Rajee Suri
press@sabin.org

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brookfield Reinsurance successfully completes Special Distribution10.12.2022 00:09:10 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BAMR) (“Brookfield Reinsurance” or the “Company”) today announced that it has completed the previously announced special distribution (the “Special Distribution”) of shares of Brookfield Asset Management Ltd. (the “Manager shares”) to the holders of our Company’s class A exchangeable limited voting shares (“class A exchangeable shares”) and class B limited voting shares. The Special Distribution The Special Distribution was completed by way of a return of capital, resulting in a reduction to the par value of the class A exchangeable shares and class B limited voting shares of our Company in the amount of US$5.481 per share. The Name Change Brookfield Reinsurance also announced today that it has changed its name to “Brookfield Reinsurance Ltd.” It is expected that the Company’s class A exchangeable shares listed on each of the New York Stock Exchange and the Toronto Stock Exchange will begin trading u

Brookfield Corporation Successfully Completes Distribution of 25% Interest in its Asset Management Business10.12.2022 00:00:34 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) (the “Corporation”) and Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) (the “Manager”) today jointly announced the completion of the public listing and distribution of a 25% interest in the Corporation’s asset management business, through the Manager, by way of a plan of arrangement (“Arrangement”). The Corporation has changed its name from Brookfield Asset Management Inc. to Brookfield Corporation, with effect from today and at the open of markets on December 12, 2022, its shares will trade under the new ticker “BN” on both stock exchanges. The Manager takes the name Brookfield Asset Management Ltd. and has been successfully listed on the New York Stock Exchange and the Toronto Stock Exchange. At the open of markets on December 12, 2022, its shares will trade under the ticker “BAM” on both stock exchanges. Shareholders can now access a leading pure-play global alternative asset manag

Brookfield Announces Upgrade to Debt Rating9.12.2022 21:50:28 CET | Press release

BROOKFIELD, NEWS, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) (“Brookfield”) today announced that it has received an upgrade on its senior unsecured debt rating from Moody’s to A3 from Baa1, reflecting the strengthening and resiliency of the inflation-linked cash flows generated across Brookfield’s three core pillars – Asset Management, Insurance Solutions and its Operating Businesses. This rating will apply to Brookfield Corporation, which will be the new name of Brookfield Asset Management Inc., after the completion of the public listing and distribution of a 25% interest in Brookfield’s asset management business. Nicholas Goodman, Chief Financial Officer, stated, “We are pleased that the continued growth in our three core pillars, the stability and resiliency of the cash flows we generate, and our conservative capitalization is being recognized in the credit upgrade we received from Moody’s. This upgrade further reinforces the key diffe

Manager’s transactions9.12.2022 20:01:25 CET | Press release

December 9, 2022 – announcement no. 12 Shares received as a result of automatic reinvestment of dividends under short-term and long-term share-based incentive programs in Chr. Hansen Holding A/S administered by a third party. Please see attachment. For further information please contact: Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364 Cristina Rønde Hefting, Senior Investor Relations Manager, Tel: +45 4072 1224 Kathrine Westermann, Head of Media Relations, Tel: +45 2381 5595 Attachment No. 12 Managers transactions

ING reports outcome of 2022 EU-wide Transparency Exercise9.12.2022 18:16:45 CET | Press release

ING reports outcome of 2022 EU-wide Transparency Exercise ING Groep N.V. notes the announcements made today by the European Banking Authority and the European Central Bank (ECB) regarding the information of the 2022 EU-wide Transparency Exercise and fulfilment of the EBA Board of Supervisors’ decision. The EBA Board of Supervisors approved the package for the EU‐wide Transparency Exercise, which since 2016 is performed on an annual basis and published along with the Risk Assessment Report (RAR). The annual transparency exercise will be based solely on COREP/FINREP data on the form and scope to assure a sufficient and appropriate level of information to market participants. The outcome of the exercise related to ING Group can be found in the annexes of the EBA website. The templates were centrally filled in by the EBA and sent afterwards for verification by banks and supervisors. Banks had the chance to correct any errors detected and to resubmit correct data through the regular supervi